Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Kevin Steinke maintains an Outperform rating on Cross Country Healthcare (CCRN) but lowers the price target from $26 to $24.
February 27, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barrington Research maintains an Outperform rating on Cross Country Healthcare but lowers the price target from $26 to $24.
While the Outperform rating suggests continued confidence in Cross Country Healthcare's performance, the reduction in price target may reflect adjustments in market conditions or company valuation that could temper short-term price optimism.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100